Press Releases Year:
DATE
Dec 18, 2017
Sort By:
NASDAQ: CNCE
TITLE
VIEW
Concert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial Officer
Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index
Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update
Nov 6, 2017
Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial
Nov 2, 2017
Concert Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 9, 2017, and Participate at Upcoming Investor Conferences
Oct 19, 2017
Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent
Aug 31, 2017
Concert Pharmaceuticals Announces Webcast at Wells Fargo Healthcare Conference
Aug 8, 2017
Concert Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Company Update
Aug 1, 2017
Concert Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017
Jul 25, 2017
Vertex and Concert Pharmaceuticals Complete Asset Purchase Agreement for CTP-656
Jul 24, 2017
Concert Pharmaceuticals Announces Termination of the HSR Act Waiting Period for CTP-656 Asset Purchase Agreement with Vertex
Jul 10, 2017
FDA Lifts Clinical Hold on Concert Pharmaceuticals Clinical Trial with CTP-543
Jun 12, 2017
Concert Pharmaceuticals Announces $30 Million Venture Debt Financing from Hercules Capital
May 30, 2017
Concert Pharmaceuticals Announces Departure of Chief Financial Officer, Ryan Daws
May 30, 2017
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
May 24, 2017
Concert Pharmaceuticals Announces Shareholder Approval of CTP-656 Asset Purchase Agreement with Vertex Pharmaceuticals
May 22, 2017
Concert Pharmaceuticals Receives Second Request from FTC Under HSR Act
May 17, 2017
Concert Pharmaceuticals Announces Clinical Hold on CTP-543 Phase 2a Trial
May 2, 2017
Concert Pharmaceuticals Reports First Quarter 2017 Financial Results
May 2, 2017
Concert Pharmaceuticals Initiates CTP-543 Phase 2 Trial in Alopecia Areata
Apr 25, 2017
Concert Pharmaceuticals to Report First Quarter 2017 Financial Results on May 2, 2017, and Present at Upcoming Investor Conferences
Mar 6, 2017
Concert Pharmaceuticals Reports Year Ended 2016 Financial Results
Mar 6, 2017
Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis
Mar 4, 2017
Concert Pharmaceuticals Presents CTP-543 Phase 1 Results at American Academy of Dermatology Annual Meeting
Mar 2, 2017
Concert Pharmaceuticals to Report Full Year 2016 Results on March 6, 2017, and Present at Upcoming Investor Conferences
Jan 20, 2017
Concert Pharmaceuticals Receives FDA Orphan Drug Designation for CTP-656 for the Treatment of Cystic Fibrosis
Jan 17, 2017
Concert Pharmaceuticals Provides Further Details on CTP-656 Development in U.S. and Europe
Dec 21, 2016
Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-656 for the Treatment of Cystic Fibrosis
Dec 14, 2016
Concert Pharmaceuticals Announces CTP-543 Positive Top-Line Phase 1 Results
Nov 8, 2016
Concert Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Company Update
Nov 1, 2016
Concert Pharmaceuticals to Report Third Quarter 2016 Financial Results on November 8, 2016, and Present at Upcoming Investor Conferences
Oct 27, 2016
Concert Pharmaceuticals Presents Poster at 2016 North American Cystic Fibrosis Conference
Sep 21, 2016
Concert Pharmaceuticals Announces Upcoming Poster Presentation at North American Cystic Fibrosis Conference
Sep 6, 2016
Concert Pharmaceuticals Expands Management Team
Sep 1, 2016
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
Aug 9, 2016
Concert Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Company Update
Aug 2, 2016
Concert Pharmaceuticals to Report Second Quarter 2016 Financial Results on August 9, 2016
Jul 6, 2016
Concert Pharmaceuticals Announces Webcast at Cantor Fitzgerald Healthcare Conference
Jun 10, 2016
Concert Pharmaceuticals Presents CTP-656 Phase 1 Results at European Cystic Fibrosis Conference
May 19, 2016
Concert Pharmaceuticals Initiates Phase 1 Trial of CTP-543 as a New Treatment for Alopecia Areata
May 17, 2016
Concert Pharmaceuticals to Present at Several Upcoming Investor Conferences
May 5, 2016
Concert Pharmaceuticals Reports First Quarter 2016 Financial Results
May 4, 2016
Concert Pharmaceuticals Unveils CTP-543 for Treatment of Alopecia Areata
Apr 28, 2016
Concert Pharmaceuticals Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-656, Lead Candidate for the Treatment of Cystic Fibrosis
Apr 28, 2016
Concert Pharmaceuticals to Report First Quarter 2016 Financial Results on May 5, 2016
Apr 14, 2016
Concert Pharmaceuticals Names Christine van Heek to Board of Directors
Mar 23, 2016
Concert Pharmaceuticals Names Meghan FitzGerald to its Board of Directors
Mar 1, 2016
Concert Pharmaceuticals Reports Fourth Quarter and Year Ended 2015 Financial Results
Feb 29, 2016
Concert Pharmaceuticals Announces CTP-656 Solid Dose Phase 1 Results Confirmed Superior Pharmacokinetic Profile to Kalydeco®
Feb 29, 2016
Concert Pharmaceuticals to Present at Several Upcoming Investor Conferences
Feb 23, 2016
Concert Pharmaceuticals to Report Full Year 2015 Results on March 1, 2016
Nov 16, 2015
Concert Pharmaceuticals Achieves $2 Million Milestone from Avanir Pharmaceuticals for Phase 3 Initiation of AVP-786 for Agitation in Patients with Alzheimer's Disease
Nov 12, 2015
Concert Pharmaceuticals Initiates Phase 1 Multiple Ascending Dose Trial with CTP-656 for Cystic Fibrosis
Nov 9, 2015
Concert Pharmaceuticals to Present at Upcoming Investor and Industry Conferences
Nov 5, 2015
Concert Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Company Update
Oct 29, 2015
Concert Pharmaceuticals to Report Third Quarter 2015 Financial Results on November 5, 2015
Oct 8, 2015
Concert Pharmaceuticals Highlights CTP-656 Phase 1 Results at North American Cystic Fibrosis Conference
Oct 8, 2015
Concert Pharmaceuticals Announces $8 Million Milestone from Celgene
Sep 22, 2015
Concert Pharmaceuticals Announces Results of a Phase 1 Trial That Demonstrates CTP-656 Achieved a Superior Pharmacokinetic Profile to Kalydeco®
Sep 2, 2015
Concert Pharmaceuticals to Present at Three Upcoming Investor Conferences
Aug 5, 2015
Concert Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Company Update
Jul 29, 2015
Concert Pharmaceuticals to Report Second Quarter 2015 Financial Results on August 5, 2015
Jun 8, 2015
Concert Pharmaceuticals Receives $50 Million Payment from Auspex Pharmaceuticals
May 27, 2015
Concert Pharmaceuticals to Present at Two Upcoming Investor Conferences
May 12, 2015
Concert Pharmaceuticals to Present at the UBS Global Healthcare Conference
May 8, 2015
Concert Pharmaceuticals Reports First Quarter 2015 Financial Results
May 7, 2015
Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update
May 1, 2015
Concert Pharmaceuticals to Report First Quarter 2015 Financial Results on May 8, 2015
Apr 7, 2015
Concert Pharmaceuticals to Present at 14th Annual Needham Healthcare Conference
Mar 24, 2015
Concert Pharmaceuticals Announces Completion of Public Offering
Mar 19, 2015
Concert Pharmaceuticals Announces Pricing of Public Offering
Mar 18, 2015
Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock
Mar 12, 2015
Concert Pharmaceuticals Initiates Phase 1 Trial Evaluating Deuterated Ivacaftor for Cystic Fibrosis
Feb 27, 2015
Concert Pharmaceuticals Reports Year End 2014 Financial Results
Feb 23, 2015
Concert Pharmaceuticals to Present at Three Upcoming Investor Conferences
Feb 20, 2015
Concert Pharmaceuticals to Report Full Year 2014 Results on February 27, 2015
Feb 4, 2015
Concert Pharmaceuticals Announces Appointment of James V. Cassella as Chief Development Officer
Dec 15, 2014
Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index
Dec 10, 2014
Concert Pharmaceuticals Names Thomas Auchincloss to Board of Directors and Chair of the Audit Committee
Dec 9, 2014
Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update
Nov 12, 2014
Concert Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Update on CTP-354 Program
Nov 11, 2014
Concert Pharmaceuticals to Present at Stifel 2014 Healthcare Conference on November 18, 2014
Nov 5, 2014
Concert Pharmaceuticals to Report Third Quarter 2014 Results on November 12, 2014
Oct 13, 2014
Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP354, Lead Candidate for the Treatment of Spasticity
Sep 17, 2014
Concert Pharmaceuticals Announces Initiation of CTP-730 Phase 1 Clinical Trial Under Celgene Collaboration
Aug 26, 2014
Concert Pharmaceuticals Achieves $2 Million Milestone for AVP-786 Under Avanir Pharmaceuticals Collaboration
Aug 21, 2014
Concert Pharmaceuticals to Present at Robert W. Baird 2014 Healthcare Conference on September 4, 2014
Aug 12, 2014
Concert Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Company Update
Aug 5, 2014
Concert Pharmaceuticals to Report Second Quarter 2014 Results on August 12, 2014
Jul 21, 2014
Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386
Jul 16, 2014
Concert Pharmaceuticals Announces FDA Lifts Partial Clinical Hold for CTP-354, A Novel Drug Candidate for Spasticity
Jul 8, 2014
Concert Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for CTP-499
May 27, 2014
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
May 14, 2014
Concert Pharmaceuticals Reports First Quarter 2014 Financial Results
May 12, 2014
Concert Pharmaceuticals to Present at the 2014 UBS Global Healthcare Conference on May 19, 2014
May 7, 2014
Concert Pharmaceuticals to Report First Quarter 2014 Results on May 14, 2014
Apr 25, 2014
Concert Pharmaceuticals Presents Positive 48Week Results from Phase 2 Clinical Trial of CTP499 in Diabetic Kidney Disease
Mar 31, 2014
Concert Pharmaceuticals Announces Filing of its Annual Report on Form 10-K
Mar 31, 2014
Concert Pharmaceuticals Reports Year End 2013 Financial Results
Mar 19, 2014
Concert Pharmaceuticals Announces CTP-499 Late Breaking Presentation at the National Kidney Foundation 2014 Spring Clinical Meeting
Mar 14, 2014
Concert Pharmaceuticals Appoints Wendell Wierenga to Board of Directors
Mar 3, 2014
Concert Pharmaceuticals Announces Exercise of Over-Allotment Option
Mar 3, 2014
Concert Pharmaceuticals to Present at the 26th Annual ROTH Conference on March 10, 2014
Feb 19, 2014
Concert Pharmaceuticals Announces Closing of Initial Public Offering
Feb 13, 2014
Concert Pharmaceuticals Announces Pricing of Initial Public Offering
Jan 23, 2014
Concert Pharmaceuticals Announces the Appointment of Ryan Daws as Chief Financial Officer
Jun 11, 2013
Concert Pharmaceuticals to Present at the 2013 Wells Fargo Securities Healthcare Conference on June 18, 2013
Jun 10, 2013
Concert Pharmaceuticals Initiates Phase 1 Clinical Trial of CTP-354, a Potential Treatment for Spasticity and Pain
Jun 5, 2013
Concert Pharmaceuticals’ Partner Avanir Pharmaceuticals Announces Accelerated Development Path for AVP-786 Following Successful Pre-IND Meeting with FDA
May 6, 2013
Concert Pharmaceuticals Announces Strategic Collaboration with Celgene Corporation to Develop Deuterium-Modified Compounds
Apr 23, 2013
Concert Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013
Feb 27, 2013
Concert Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference on March 5, 2013
Feb 26, 2013
Jazz Pharmaceuticals plc and Concert Pharmaceuticals Announce Worldwide Licensing Agreement to Develop and Commercialize Deuterium-Modified Sodium Oxybate
Feb 19, 2013
Concert Pharmaceuticals Announces Completion of Enrollment in Phase 2 CTP-499 Clinical Trial for the Treatment of Diabetic Kidney Disease
Feb 7, 2013
Concert Pharmaceuticals Announces Milestone Achievement in Avanir Pharmaceuticals Collaboration
Dec 10, 2012
Concert Pharmaceuticals Presents Findings Demonstrating Enhanced Potency of CTP-221, a Deuterated S-Enantiomer of Lenalidomide
Nov 27, 2012
Concert Pharmaceuticals’ CTP-499 for Diabetic Kidney Disease Selected as a Top 10 Project to Watch by Windhover
Nov 27, 2012
Concert Pharmaceuticals’ Partner Avanir Pharmaceuticals Provides Clinical Study Update on CTP-786/AVP-786
Nov 5, 2012
Concert Pharmaceuticals Announces Poster Presentation at the 2012 American Society of Hematology Annual Meeting
Nov 1, 2012
Concert Pharmaceuticals Presents Preclinical Results Demonstrating CTP-499, a Novel Treatment for Diabetic Kidney Disease, Ameliorated Renal Fibrosis and Inflammation In Vivo; Data Presented at Kidney Week 2012
Oct 22, 2012
Concert Pharmaceuticals Announces Issuance of U.S. Patent for its Lead Drug Candidate CTP-499
Oct 11, 2012
Concert Pharmaceuticals Announces Preclinical Poster Presentation at the American Society of Nephrology Kidney Week 2012
Aug 8, 2012
Concert Pharmaceuticals to Present at the 2012 Wedbush PacGrow Life Sciences Conference on August 15, 2012
May 11, 2012
Concert Pharmaceuticals Presents Clinical Results Demonstrating CTP-499 is Well-Tolerated in Patients with Stage 3 Chronic Kidney Disease; Results Presented at National Kidney Foundation 2012 Spring Clinical Meetings
Mar 29, 2012
Concert Pharmaceuticals to Present at the Needham 2012 Healthcare Conference on April 3, 2012
Mar 5, 2012
Concert Pharmaceuticals and Fast Forward Announce Collaboration to Advance Novel Treatment for Spasticity and Pain in Multiple Sclerosis
Mar 5, 2012
Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-499 for the Treatment of Diabetic Nephropathy
Feb 29, 2012
Avanir Pharmaceuticals and Concert Pharmaceuticals Announce License Agreement to Develop and Commercialize Deuterium-Modified Dextromethorphan for Disorders of the Nervous System
Feb 28, 2012
Concert Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference on March 6, 2012
Jan 28, 2012
Concert Pharmaceuticals to Present at Epilepsy Pipeline Update Conference
Jan 18, 2012
New Patents Expand Concert Pharmaceuticals’ Patent Estate of Deuterium-Based Therapeutics; 25 Patents Issued Worldwide
Jan 3, 2012
Concert Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 10, 2012
Nov 21, 2011
Concert Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference on November 30, 2011
Nov 15, 2011
Concert Pharmaceuticals Announces NIH Research Collaboration for Rare and Neglected Diseases
Nov 14, 2011
Concert Presents Phase 1 Data for CTP-499 at ASN Kidney Week Meeting; Supports Advancement into Phase 2 in Diabetic Nephropathy Patients
Nov 14, 2011
Concert Pharmaceuticals Presents Preclinical Data for Novel GABA(A) Subtype-Selective Modulator at Neuroscience 2011; Potential Treatment for Multiple GABA-Based Disorders Including Spasticity and Pain
Oct 19, 2011
Concert Pharmaceuticals Announces Data Presentations at Neuroscience 2011; Demonstrates Potential of Deuterium-Containing GABAA Modulators
Oct 19, 2011
Concert Pharmaceuticals Announces CTP-499 Data Presentations at the American Society of Nephrology (ASN) Kidney Week Meeting
Sep 29, 2011
Concert Pharmaceuticals Announces Issuance of 15th US Patent Supporting DCE Platform™ Approach; Receives New Patent for Use of C21191 in Spasticity
Aug 9, 2011
Concert Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
Jul 20, 2011
Concert Pharmaceuticals’ Deuterium-Modified Boceprevir Demonstrates Enhanced Metabolic Stabilization and Improved Drug Properties; Findings Published in Journal of Labelled Compounds and Radiopharmaceuticals
Jun 20, 2011
Concert Pharmaceuticals Announces Advancement of Novel Drug Candidates in Kidney Disease and Spasticity
Jun 20, 2011
Concert Pharmaceuticals Announces Milestone Achievement in GlaxoSmithKline Collaboration
May 2, 2011
Concert Pharmaceuticals Presents Preclinical Data on Novel Deuterium-Containing Drug Compound at Antiepileptic Drug Trials XI Conference; Sigma-1 Agonist, C-10068, Shown to Have Anti-Convulsant and Neuroprotective Effects
Apr 12, 2011
Concert Pharmaceuticals Expands Regulatory and Clinical Leadership with New Appointments Mark Roessel Named Vice President of Regulatory Affairs and Quality Assurance; LuAnn Sabounjian Named Vice President, Clinical Operations
Mar 29, 2011
Concert Pharmaceuticals to Present at the Needham Healthcare Conference on April 5, 2011
Mar 29, 2011
Concert Pharmaceuticals Advances Novel Chronic Kidney Disease Treatment, CTP-499, in Phase 1 Clinical Study; First-in-Class Drug Candidate from Deuterium Platform Has AntiInflammatory, Anti-Fibrotic, and Anti-Oxidant Properties
Mar 1, 2011
Concert Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference on March 8
Feb 2, 2011
Concert Pharmaceuticals Enters Into a Cooperative Research and Development Agreement with Walter Reed Army Institute of Research to Evaluate Neuroprotective Drug Compound; Advances Concert’s R&D for Novel Drugs to Treat Seizure-Generating Diseases a
Jan 19, 2011
James E. Shipley, M.D., Named Chief Medical Officer of Concert Pharmaceuticals; Additional Management Team Announcement with Promotion of Robert Silverman
Jan 13, 2011
New Patents Continue to Issue for Concert Pharmaceuticals Deuterium Chemistry Intellectual Property Estate
Dec 9, 2010
Concert Pharmaceuticals Broadens Management Team and Expands Product Advisory Board
Nov 2, 2010
Concert Pharmaceuticals Awarded $488,000 Therapeutic Discovery Project Grants
Oct 27, 2010
Concert Pharmaceuticals to Present at the Oppenheimer 21st Annual Healthcare Conference on November 3, 2010
Sep 9, 2010
Concert Pharmaceuticals to Present at the Stifel Nicolaus Healthcare Conference on September 16, 2010
Aug 10, 2010
Gregory Miller Joins Concert Pharmaceuticals as Head of Business and Corporate Development
Aug 3, 2010
Concert Pharmaceuticals to Present at Canaccord Genuity Global Growth Conference on August 10, 2010
Apr 28, 2010
Concert Pharmaceuticals to Participate in Drug Discovery and Development Panel at 2010 BIO International Convention
Mar 31, 2010
Concert Pharmaceuticals Granted Patent for Deuterated Paroxetine Compounds, Including CTP-347
Mar 1, 2010
Concert Pharmaceuticals to Present at the 30th Annual Cowen and Company Health Care Conference on Monday, March 8
Jan 4, 2010
Concert Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11
Nov 9, 2009
Concert Pharmaceuticals Initiates Phase 1b Clinical Trial of CTP-518, Protease Inhibitor for Treatment of HIV
Nov 3, 2009
Concert Pharmaceuticals to Participate on a Private Company Panel at the Merriman Curhan Ford 6th Annual Investor Summit
Oct 29, 2009
Concert Pharmaceuticals’ Roger Tung Awarded 2009 Mass High Tech All Star Award
Oct 20, 2009
Concert Pharmaceuticals to Present at Second Annual Boston Biotech R&D Conference
Oct 13, 2009
Concert Pharmaceuticals Selected by AlwaysOn as an OnDC Top 100 Winner; Recognized for Innovative Technology for Game-Changing New Medicines
Sep 14, 2009
Concert Pharmaceuticals Presents Clinical Results Demonstrating Reduced Drug-Drug Interactions with a Deuterium-Modified Compound; Phase I Results Presented at American College of Clinical Pharmacology
Sep 3, 2009
Concert Pharmaceuticals to Present at the Thomas Weisel Partners 2009 Healthcare Conference on September 10, 2009
Jun 2, 2009
Concert Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium Modified Drugs
Jun 1, 2009
Concert Pharmaceuticals to Participate in the Private Company Forum at the 30th Annual Goldman Sachs Global Healthcare Conference
May 11, 2009
Concert Pharmaceuticals Granted Patents on Deuterium-Modified Compounds
Mar 16, 2009
Concert Pharmaceuticals Announces Positive Results from Phase I Clinical Study of CTP-347; First Clinical Demonstration of Concert's Technology Platform
Mar 9, 2009
Concert Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference on March 16, 2009
Jan 5, 2009
Concert Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on Monday, January 12
Nov 24, 2008
Concert Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
Oct 28, 2008
Concert Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
Oct 27, 2008
Concert Pharmaceuticals Announces Preclinical Results Suggesting Potential for Once Daily Dosing of Novel Oxazolidinone Antibiotic; Findings Presented at ICAAC/IDSA
Oct 15, 2008
Concert Pharmaceuticals to Present at First Annual Boston Biotech R&D Conference
Oct 6, 2008
Steven Bernitz Joins Concert Pharmaceuticals as Chief Business Officer
Sep 29, 2008
Concert Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
Sep 25, 2008
Concert Pharmaceuticals Initiates CTP-347 Phase I Clinical Trial; Potential Best-in-Class NonHormonal Treatment for Vasomotor Symptoms
Sep 25, 2008
Concert Pharmaceuticals Presents Preclinical Results Supporting Co-Administration of CTP-347 and Tamoxifen; Results Presented at the North American Menopause Society's 2008 Annual Meeting
Jun 24, 2008
Concert Pharmaceuticals Named One of the "Fierce 15" Biotech Companies of 2008
Apr 30, 2008
Concert Pharmaceuticals Raises $37 Million in Series C Financing
Mar 11, 2008
Concert Pharmaceuticals to Present at the Cowen and Company 28th Annual Healthcare Conference
Jan 3, 2008
Concert Pharmaceuticals Names W. James O’Shea and Daniel Grau to Product Advisory Board
Jan 2, 2008
Concert Pharmaceuticals to Present at the 26th Annual JPMorgan Healthcare Conference
Dec 13, 2017 Nov 9, 2017
$ 25.87 Day High: 26.47 Day Low: 25.75 Volume: 400,366
+0.01 (0.04%) 4:00 PM ET on Dec 29, 2017
Delayed ~20 min., by eSignal.
3 mo.
= add release to Briefcase
6 mo.
IR Contact Justine E. Koenigsberg Vice President, Corporate Communications and Investor Relations 781.674.5284
[email protected]
1 yr.